Sunflower Pharmaceutical Group Co.,Ltd
Summary
Revenue :
000,000 M USD
Finance :
000,000 M USD
Earning Cap :
000,000 M USD
Invest :
000,000 M USD
R & D :
0000 People
Growth :
00% AGR
DIGDAL CAP
Overview
| General Introduction | Sunflower Pharmaceutical Group Co., Ltd. is a well-known pharmaceutical enterprise with the mission of "making good medicine for the people; caring for the healthy growth of Chinese children, and ensuring the safety of Chinese children's medication", with brand OTC products as the core, covering the entire industry chain of research and development, production, and sales. The predecessor of the group was the former state-owned Wuchang Pharmaceutical Factory in Heilongjiang Province. In 1998, it was restructured into a private enterprise - Heilongjiang Sunflower Pharmaceutical Co., Ltd., which continued to grow and grow. In 2005, Sunflower Pharmaceutical Group Co., Ltd. was established. The group currently has 33 subsidiaries, including 13 pharmaceutical production enterprises, 6 pharmaceutical companies, 4 pharmaceutical research institutes, 2 medicinal herb planting bases, and 1 pharmaceutical packaging company, headquartered in Harbin. Listed in Shenzhen at the end of 2014, stock code: 002737. Sunflower Pharmaceutical Group, led by traditional Chinese patent medicines and simple preparations and flanked by "chemical medicine, biological medicine" and "health care products", has formed a comprehensive layout of product pipelines in the six fields of "pediatrics, gynecology, digestive system, respiratory colds, rheumatism and bone diseases, cardio cerebrovascular diseases", with a rich product line, a total of 21 dosage forms, 257 products in production, and 1200 drug approval numbers. Among them, there are nearly 100 approval numbers for children's medicine and over 60 children's medicine products being sold. Xiaokuihua Children's Medicine has an unshakable advantage in the same category in the OTC field in terms of sales scale, product quantity, and scale of individual products. The company is an OTC large-scale enterprise with a "dual brand umbrella". The two well-known consumer brands "Sunflower" and "Little Sunflower" have built a consumer trust foundation for the company's adult and children's medicines. After more than 20 years of development, the company has adopted combination marketing models such as "brand model, general medicine model, prescription model, big health model, and new retail model" based on product characteristics and sales terminal differences, and has constructed a unique combination marketing and full model integration model in the industry, which has attracted attention and imitated by the industry. The company has been jointly awarded the "Outstanding Contribution Unit for Children's Safe Drug Use" by four units including the World Health Organization Children's Health Cooperation Center; The "Xiaokuihua" brand has been listed on the "Healthy China · Chinese Medicine Brand List" for twelve consecutive times, and has remained at the top of the list of children's cold and cough medication; Xiaokui Huapai Xiaoer Feire Kechuan Oral Liquid/Granule has been recognized as "the first traditional Chinese patent medicines and simple preparations in pediatric cold and cough category" by China Non prescription Drug Association for many years (2016~2019). The number of pharmaceutical enterprises above designated size in China has reached over 7000. Ranked 75th in the "2021 Top 100 List of China's Pharmaceutical Industry" issued under the guidance of the 39th National Pharmaceutical Industry Information Conference hosted by the China Pharmaceutical Industry Information Center in December 2022; In September 2022, the Ministry of Commerce of the People's Republic of China announced that the two subsidiaries ranked 59th and 79th respectively in the "Top 100 Main Business Income of Drug Wholesale Enterprises in 2021"; Ranked 15th in the "Top 100 Chinese Traditional Chinese Medicine Enterprises" released at the China Medical and Health Industry Symbiosis Conference in July 2022, and won this honor for four consecutive years (2018-2021); In the "Decision of the Leading Group for the Development of Non Public Owned Economy (Small and Medium sized Enterprises) in Heilongjiang Province on Commending Excellent Private Enterprises" announced at the November 2022 Heilongjiang Provincial Conference on the Development of Private Economy, Sunflower Pharmaceutical Group ranked 7th among the Top 50 Accumulated Taxpaying Private Enterprises in Heilongjiang Province and 1st among pharmaceutical enterprises. The company is currently an executive vice president unit of the Medical and Pharmaceutical Chamber of Commerce of the All China Federation of Industry and Commerce, a vice president unit of the China Pharmaceutical Enterprise Management Association, a vice president unit of the China Pharmaceutical Business Association, a member unit of the China Traditional Chinese Medicine Association, a vice president unit of the Chronic Disease Professional Committee of the China Traditional Chinese Medicine Association, and a director unit of the China OTC Drug Association. The company has been awarded honorary titles such as "National May Day Labor Award", "National Advanced Enterprise with Double Love and Double Evaluation", "National Red Flag Unit for Enterprise Trade Union Work", "National Model Employee Home", "National AAA Credit Enterprise with Credit Evaluation", "Advanced Enterprise in Implementing Excellent Performance Model", and "Excellent Unit in Enterprise Culture Construction". |
| Headquarter | Harbin |
| Establish Date | 9/7/2005 |
| Listed Code | 002737.SZ |
| Listed Date | 12/30/2014 |
| Chairman | Guan Yuxiu. |
| CEO | Close one. |
| Website | www.kuihuayaoye.com |
Buy Premium Now
$15/month billed now
View the full stack of insights immediately
Or 7 Days Free Charge for Trial
See feature available in the Trial and Premium
See our Solution and Servicetrial.solutionservice.trial
See our Uniquness and Value deliveringtrial.solutionservice.trial
